Effects of recombinant human growth hormone on the development of burn scarring

Juan P. Barret, Peter Dziewulski, Marc G. Jeschke, Steven Wolf, David Herndon

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Anabolic agents, such as recombinant human growth hormone (rhGH), have been used effectively to ameliorate the catabolic response to burn injury and to improve wound-healing. However, in experimental animal models, growth hormone has also been associated with increased renal scarring. The effect of rhGH on the development of human scarring is unknown. Therefore, the purpose of this study was to assess the effect of rhGH on the scarring of human skin after burn injury. A series of 94 patients was studied in a prospective randomized double-blind clinical trial. Patients receiving 0.2 mg/kg/day subcutaneous rhGH during their acute hospital stays presented with the same quality and intensity of scarring as patients receiving a placebo. Similar reconstructive needs also resulted. The treatment of severely burned children with recombinant human growth hormone during the acute-phase hospital course did not increase scarring of the burn wound.

Original languageEnglish (US)
Pages (from-to)726-729
Number of pages4
JournalPlastic and Reconstructive Surgery
Volume104
Issue number3
DOIs
StatePublished - Sep 1999

Fingerprint

Human Growth Hormone
Growth Hormone
Cicatrix
Wounds and Injuries
Anabolic Agents
Human Development
Wound Healing
Length of Stay
Animal Models
Placebos
Clinical Trials
Kidney
Skin

ASJC Scopus subject areas

  • Surgery

Cite this

Effects of recombinant human growth hormone on the development of burn scarring. / Barret, Juan P.; Dziewulski, Peter; Jeschke, Marc G.; Wolf, Steven; Herndon, David.

In: Plastic and Reconstructive Surgery, Vol. 104, No. 3, 09.1999, p. 726-729.

Research output: Contribution to journalArticle

Barret, Juan P. ; Dziewulski, Peter ; Jeschke, Marc G. ; Wolf, Steven ; Herndon, David. / Effects of recombinant human growth hormone on the development of burn scarring. In: Plastic and Reconstructive Surgery. 1999 ; Vol. 104, No. 3. pp. 726-729.
@article{adfc11c442454d33a34883dc5e7770cc,
title = "Effects of recombinant human growth hormone on the development of burn scarring",
abstract = "Anabolic agents, such as recombinant human growth hormone (rhGH), have been used effectively to ameliorate the catabolic response to burn injury and to improve wound-healing. However, in experimental animal models, growth hormone has also been associated with increased renal scarring. The effect of rhGH on the development of human scarring is unknown. Therefore, the purpose of this study was to assess the effect of rhGH on the scarring of human skin after burn injury. A series of 94 patients was studied in a prospective randomized double-blind clinical trial. Patients receiving 0.2 mg/kg/day subcutaneous rhGH during their acute hospital stays presented with the same quality and intensity of scarring as patients receiving a placebo. Similar reconstructive needs also resulted. The treatment of severely burned children with recombinant human growth hormone during the acute-phase hospital course did not increase scarring of the burn wound.",
author = "Barret, {Juan P.} and Peter Dziewulski and Jeschke, {Marc G.} and Steven Wolf and David Herndon",
year = "1999",
month = "9",
doi = "10.1097/00006534-199909030-00017",
language = "English (US)",
volume = "104",
pages = "726--729",
journal = "Plastic and Reconstructive Surgery",
issn = "0032-1052",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effects of recombinant human growth hormone on the development of burn scarring

AU - Barret, Juan P.

AU - Dziewulski, Peter

AU - Jeschke, Marc G.

AU - Wolf, Steven

AU - Herndon, David

PY - 1999/9

Y1 - 1999/9

N2 - Anabolic agents, such as recombinant human growth hormone (rhGH), have been used effectively to ameliorate the catabolic response to burn injury and to improve wound-healing. However, in experimental animal models, growth hormone has also been associated with increased renal scarring. The effect of rhGH on the development of human scarring is unknown. Therefore, the purpose of this study was to assess the effect of rhGH on the scarring of human skin after burn injury. A series of 94 patients was studied in a prospective randomized double-blind clinical trial. Patients receiving 0.2 mg/kg/day subcutaneous rhGH during their acute hospital stays presented with the same quality and intensity of scarring as patients receiving a placebo. Similar reconstructive needs also resulted. The treatment of severely burned children with recombinant human growth hormone during the acute-phase hospital course did not increase scarring of the burn wound.

AB - Anabolic agents, such as recombinant human growth hormone (rhGH), have been used effectively to ameliorate the catabolic response to burn injury and to improve wound-healing. However, in experimental animal models, growth hormone has also been associated with increased renal scarring. The effect of rhGH on the development of human scarring is unknown. Therefore, the purpose of this study was to assess the effect of rhGH on the scarring of human skin after burn injury. A series of 94 patients was studied in a prospective randomized double-blind clinical trial. Patients receiving 0.2 mg/kg/day subcutaneous rhGH during their acute hospital stays presented with the same quality and intensity of scarring as patients receiving a placebo. Similar reconstructive needs also resulted. The treatment of severely burned children with recombinant human growth hormone during the acute-phase hospital course did not increase scarring of the burn wound.

UR - http://www.scopus.com/inward/record.url?scp=0032839737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032839737&partnerID=8YFLogxK

U2 - 10.1097/00006534-199909030-00017

DO - 10.1097/00006534-199909030-00017

M3 - Article

VL - 104

SP - 726

EP - 729

JO - Plastic and Reconstructive Surgery

JF - Plastic and Reconstructive Surgery

SN - 0032-1052

IS - 3

ER -